Dr. Steffen Ernst, the founder of Xzencis, will be the keynote speaker at the ApconiX DSF 2024 Drug Safety Forum in London. This event, held on October 17, 2024, at the Wellcome Collection on Euston Road, focuses on translational safety in drug development. The symposium is titled “A Patient First Approach to Translational Safety: From Nonclinical to Clinical” and aims to explore the complex safety value chain in the pharmaceutical industry. Dr. Ernst’s address, “Translational Safety Medicine by Examples,” will highlight the practical importance of ensuring that the safety value chain remains intact throughout drug development.
The forum will feature discussions among industry toxicologists, patient safety professionals, and pharmacovigilance physicians on how translational safety bridges nonclinical and clinical stages in drug safety. Dr. Ernst will also lead an expert Q&A panel, fostering deeper insights into this critical aspect of pharmaceutical development.
Xzencis, the company led by Dr. Ernst, specializes in consultancy services that span the pharmaceutical value chain, including toxicology, patient safety, and pharmacovigilance, assisting life science companies in overcoming regulatory challenges.
